Skip to main content

Antimicrobial Stewardship

Clinical Strengths

RUMC and CCH Stroger Hospital boast longstanding and effective antimicrobial stewardship programs (ASPs), whose precepts are fully integrated into ID practice and training. RUMC’s ASP has been designated an IDSA Centers of Excellence in 2018. Led by Dr. Won (Medical Director) and Dr. Shankaran (Associate Medical Director), the program has 2 full time adult ID pharmacists, 1 pediatric ID pharmacist, 1 pediatric ID physician, and the program is assisted by 6 rotating hospital pharmacy residents and several ICU/Emergency room pharmacists. Stroger’s ASP, with 2 ID pharmacists and led by Dr. Schwartz since 1994, has innovated in numerous domains, consulting regularly with the Illinois Department of Public Health and collaborating in research with the CDC.

Fellows receive didactics in antimicrobial use and stewardship as part of their core training. They participate in stewardship interventions during their inpatient clinical service by reviewing the records of and intervening when needed for patients with newly positive blood cultures, by fielding off-hour requests for restricted antimicrobials, and by learning, modeling and teaching on core ASP concepts in their everyday clinical interactions with non-ID colleagues. In addition, interested fellows are welcome to participate in regular ASP meetings and in ASP-related quality improvement and research projects, as described below.

Research Excellence

Our ASPs provide ample opportunities for interested fellows to participate in mentored clinical research, including an option for a third year of dedicated research training. Recent stewardship-related research projects include:

  • An ethnographic approach to interrogating antimicrobial stewardship
  • Analysis of enteric gram negative bacilli susceptibilities to inform empiric antimicrobial recommendations
  • Impact of antimicrobial stewardship intervention with and without rapid pathogen identification for bloodstream infections
  • Prediction of infection by carbapenem-only susceptible organisms in hospitalized patients
  • Impact of procalcitonin-based and conventional antimicrobial stewardship on antimicrobial use and resistance in the RUSH and Stroger Hospital MICUs
  • Stewardship collaboration with the microbiology laboratory in the era of rapid diagnostic techniques
  • Clinical epidemiology of hospital anti-pseudomonal beta-lactam use: guideline concordance by indication and clinical findings

Recent stewardship projects of ID fellow:

  • 2021: Revision by all 10 ID fellows, RUMC empiric antibiotic guidelines
  • 2021: Haseeba Khan: Revision of 2020 RUMC inpatient antibiogram
  • 2021: Hina Farooq: Creation of educational training modules for RUMC nurses
  • 2021: Eun Sun Lee: Revision of outpatient antibiogram and outpatient empiric treatment guidelines
  • 2020-2021: Elias Baied: Effectiveness of antibiotic treatment guidelines in reducing antibiotic use in COVID-19 patients at RUMC
  • 2020: Eric Bhaimia: COVID-19 antibiotic treatment algorithm
  • 2020: Eric Bhaimia: Micafungin dosing treatment guidelines in BMT patients
  • 2020: Subina Gurung: Review of levofloxacin usage at RUMC
  • 2019-2020: Laura Hernandez-Guarin: Perioperative cefazolin use for penicillin allergic patients
  • 2019: Sarah Sansom: Analyzing impact of new CLSI levofloxacin susceptibility cut-offs on E. coli and Pseudomonas isolates at RUMC
  • 2019: Aamir Kazi: Duration of antibiotics guidelines
  • 2019: Aamir Kazi, Laura Hernandez-Guarin, Sarah Sansom: Inpatient and outpatient levofloxacin guidelines
  • 2018-2019: Aamir Kazi: Effectiveness of fellow driven versus pharmacy driven antibiotic stewardship intervention for inpatient levofloxacin use at RUMC
  • 2018-2019: Nyal Siddiqui: Development of fecal transplant guidelines for severe C. difficile
  • 2017: Enrique Cornejo Cisneros, Masters of Clinical Research Thesis, Impact of Antimicrobial Stewardship Intervention for blood stream infections with and without rapid pathogen identification on antimicrobial use and patient outcomes

Recent stewardship poster presentations, abstracts, and publications:

  • 2020: Rynkiwich K, Schwartz S, Won S, Stoner S. Perceptions of Antimicrobial Stewardship Among Infectious Disease Physicians at Two Affiliated Teaching Hospitals. Presented at SHEA 2020 (online)
  • 2019: Rynkiwich K, Schwartz S, Won S, et. al. An Ethnographic Approach to Interrogating Antimicrobial Stewardship at US Teaching Hospitals. Presented at 2019 ID Week.
  • 2019: Kazi A, Sansom S, Varughese C, Hogdson H, Won S. Love thy Steward-Who Does Not Love Antimicrobial Stewardship?. Presented at 2019 ID Week.
  • 2019: Sansom S, Moore N, Kazi A, Won S. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aureginoasa: Is It Time to Restrict Empiric Fluoroquinolone Use?. Presented at 2019 ID Week.
  • 2018: Hodgson H, O'Donnell P, Won S, Wang S. 224. Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention. Presented at 2018 ID Week.
  • 2018: Wang S, Won S, Bandi S, Tobin M, Beshir M, Ravindran S, Shields B et al. "1792. Assessing Outcomes of Antimicrobial Stewardship Interventions Along With a Hospital-Wide With a Hospital-Wide β-Lactam Allergy Guideline Through Aztreonam Use: A 5-year Observation. " In Open Forum Infectious Diseases, vol. 5, no. suppl_1, pp. S508-s508. US: Oxford University Press. 
  • 2018: Hodgson H, O'Donnell P, Won S, Wang S. 224. Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention. In Open Forum Infectious Diseases (Vol. 5, No. Suppl 1, pp. S97-s97).
  • 2017: Toy C, Peksa G, Wang S, Varughese C, Won S. Impact of an antimicrobial stewardship intervention on antibiotic prescribing practices for community-acquired acute uncomplicated cystitis in the emergency department. In Open Forum Infectious Diseases (Vol. 4, No. Suppl 1, p. S270). Oxford University Press.

Recent stewardship abstracts and publications through Stroger Hospital:

  • Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial Stewardship: how the microbiology laboratory can right the ship. Clin Microbiol Rev 2016;30:381-407.
  • Schwartz DN. Antimicrobial stewardship in US hospitals: is the cup half-full yet? Clin Infect Dis 2016;63:450-452.
  • Schwartz DN, McConeghy KW, lyles RD, Wu U, Glowacki RC, Itokazu GS, Kieszkowski P, Xiang Y, Hota B, Weinstein RA. Computer-assisted antimicrobial recommendations for optimal therapy: analysis of prescribing errors in an antimicrobial stewardship trial. Infect Control Hosp Epidemiol 2017; 38(7):854-859 (Epub June 2, 2017).
  • Peglow SR, Itokazu G, Williams B, Schwartz DN and the Illinois Collaborative for Healthcare Antimicrobial Stewardship Enhancement (ICHASE). Integrating Retrospective Antimicrobial (AM) Use Audit with Physician (MD) Education and Prospective Post-Prescriptive Review with MD Feedback: Proof of Concept with Focus on Diabetic Foot Infections (DFIs). Poster presentation at IDWeek 2014, October 8-12, Philadelphia PA, abstract 208.
  • Morency-Potvin P, Itokazu GS, Glowacki RC, Schwartz DN. Optimizing unrestricted anti-pseudomonal beta-lactam (APBL) antibiotic use: appropriate indication selection is necessary but not sufficient. European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, April 9 – 12, 2016; abstract EV0671.
  • Schwartz DN, Alu C, Morency-Potvin P, Itokazu G. Catalyst for antimicrobial stewardship improvement (CASI): a pilot implementation guidance program for Illinois acute care hospitals. Poster presentation at the Society for Healthcare Epidemiology of America, St. Louis, MO, March 29-31, 2017, abstract 355.

Other Opportunities

We are fully committed to giving our fellows a robust training in stewardship. Not only will he/she be able to participate in daily stewardship rounds and making calls and recommendations to physicians, but he/she can participate or lead any number of ongoing stewardship projects, eg. Indications for all antimicrobials, 48 hour time out, lead multi-disciplinary and multi-specialty development of guidelines/order sets, evaluation of antimicrobials to be added to formulary and/or to the restricted list, learn to generate and interpret stewardship metrics, and give educational talks to house staff and different service lines. As RUMC is part of a network of RUSH Health, he/she will also be able to help develop system-wide guidelines. Other opportunities include participating in weekly stewardship meetings, quarterly anti-infective subcommittee meetings, bimonthly PNT (Pharmacy, Nutrition, and Therapeutics) committee meetings, and quarterly presentations to hospital quality leadership. Regarding formal education, he/she will be enrolled in the IDSA’s Core Antimicrobial Stewardship curriculum, which we are piloting from July 2018.